S211 Analyze of risk factors affecting the outcomes of Docetaxel – Prednisolone combination in the treatment of metastatic castration-resistant prostate cancer: A single center study

2013 ◽  
Vol 12 (4) ◽  
pp. e1319, S211a-e1319, S211b
Author(s):  
B. Arslan ◽  
B. Gunlusoy ◽  
T. Degirmenci ◽  
Z. Kozacioglu ◽  
I.H. Bozkurt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Castration Resistant Prostate Cancer ◽  
Single Center ◽  
Factors Affecting ◽  
Castration Resistant ◽  
Single Center Study ◽  
Center Study

scholarly journals PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study

2020 ◽  
Vol 62 (1) ◽  
pp. 88-91 ◽  
Author(s):  
Manuel Weber ◽  
Claudia Kurek ◽  
Francesco Barbato ◽  
Matthias Eiber ◽  
Tobias Maurer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Single Center ◽  
Castration Resistant ◽  
Psma Ligand ◽  
Single Center Study ◽  
Center Study

scholarly journals Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study

2020 ◽  
Vol 61 (6) ◽  
pp. 588
Author(s):  
Seonggyu Byeon ◽  
Hyera Kim ◽  
Jinchul Kim ◽  
Minsuk Kwon ◽  
Joon Young Hur ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Single Center ◽  
Castration Resistant ◽  
Single Center Study ◽  
Center Study

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

Oncology ◽  
2016 ◽  
Vol 92 (2) ◽  
pp. 94-100 ◽  
Author(s):  
Giuseppe Cicero ◽  
Rossella De Luca ◽  
Patrizia Dorangricchia ◽  
Antonio Galvano ◽  
Giuseppe Lo Re ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Castration Resistant Prostate Cancer ◽  
Single Center ◽  
Castration Resistant ◽  
Single Center Study ◽  
Center Study

scholarly journals The Relationship Between Breast Cancer and Risk Factors: A Single-Center Study

2017 ◽  
Vol 13 (3) ◽  
pp. 145-149 ◽  
Author(s):  
Arzu Ozsoy ◽  
Nurdan Barca ◽  
Betul Akdal Dolek ◽  
Hafize Aktas ◽  
Eda Elverici ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Single Center ◽  
Single Center Study ◽  
The Relationship ◽  
Center Study

scholarly journals SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES

2018 ◽  
Vol 14 (3) ◽  
pp. 120-127 ◽  
Author(s):  
A. S. Markova ◽  
V. B. Matveev ◽  
B. M. Nazranov
Keyword(s):  
Prostate Cancer ◽  
Sequential Therapy ◽  
Therapeutic Agents ◽  
Continuous Treatment ◽  
Castration Resistant Prostate Cancer ◽  
Treatment Standards ◽  
Factors Affecting ◽  
Castration Resistant ◽  
Line Therapy ◽  
Significant Factors

Currently, doctors have at their disposal a number of drugs prolonging life of patients with castration-resistant prostate cancer (CRPC). The majority is approved for use as the 1st line therapy and, in absence of direct comparison, is considered potentially equally effective. Patients with CRPC need continuous treatment for suppression of disease progression resulting in sequential use of therapeutic agents. Modern standards and recommendations do not provide a clear algorithm for prescription, therefore an individual approach is necessary taking in account various factors of a particular case ranging from previous therapies to patients’ preferences. This article considers the most significant factors affecting CRPC therapy selection and ways of therapy optimization in compliance with the established treatment standards and taking into account the list of drugs approved for use in Russia.

Sign in / Sign up

Export Citation Format

Share Document